"Hela人宮頸癌復(fù)蘇細(xì)胞保種中心|帶STR證書

傳代比例：1:2-1:4(首次傳代建議1:2)

生長特性：貼壁生長

細(xì)胞復(fù)蘇相關(guān)注意事項(xiàng)：１.取細(xì)胞的過程中注意帶HAO防凍手套，護(hù)目鏡。此項(xiàng)尤為重要，細(xì)胞凍存管可能漏入，解凍時(shí)凍存管中的氣溫急劇上升，可導(dǎo)致爆炸。２.凍存的問題：凍存的配置已是常識(shí)，在這里不作詳述，但二甲基亞砜(DMSO )對細(xì)胞不是完全無毒副作用，在常溫下，二甲基亞砜對細(xì)胞的毒副作較大，因此，必須在１-２min內(nèi)使凍存完全融化。如果復(fù)蘇溫度太慢，會(huì)造成細(xì)胞的損傷，二甲基亞砜(DMSO)ZuiHAO選擇進(jìn)口產(chǎn)品。３.離心前須加入少量培養(yǎng)。細(xì)胞解凍后二甲基亞砜濃度較GAO，注意加入少量培養(yǎng)可稀釋其濃度，以減少對細(xì)胞的損傷。４.離心問題：目前主要有兩種見解。一種是解凍后的細(xì)胞懸直接吹打均勻后分裝到培養(yǎng)瓶中進(jìn)行培養(yǎng)，第二天換。因?yàn)殡x心的目的是兩個(gè)，去除DMSO，去除死細(xì)胞，這個(gè)是標(biāo)準(zhǔn)流程，但對一般人來說，把握不HAO離心轉(zhuǎn)速和時(shí)間，轉(zhuǎn)的不夠活細(xì)胞沉底的少，細(xì)胞就全被扔掉了，轉(zhuǎn)過了活細(xì)胞會(huì)受壓過大，死亡。此外在操作過程中容易污染，所以不推薦。另一種說法為細(xì)胞懸中含有二甲基亞砜(DMSO)，DMSO對細(xì)胞有一定的毒副作用，所以須將離心后的體前倒凈，且一定倒干凈。我在試驗(yàn)中按照常規(guī)的離心分裝的方法進(jìn)行復(fù)蘇，結(jié)果無異常。５.細(xì)胞貼壁少的問題：教科書中說明凍存細(xì)胞解凍時(shí)１ml細(xì)胞要加１０ml-１５ml培養(yǎng)，而在我的試驗(yàn)中的經(jīng)驗(yàn)總結(jié)為培養(yǎng)基越少細(xì)胞越容易貼附。６.復(fù)蘇細(xì)胞分裝的問題：試驗(yàn)中我的經(jīng)驗(yàn)總結(jié)為復(fù)蘇１管細(xì)胞一般可分裝到１-２只培養(yǎng)瓶中，分裝過多，細(xì)胞濃度過低，不利于細(xì)胞的貼壁。７.加培養(yǎng)基的量放入問題：這個(gè)量的多少的把握主要涉及到的問題DMSO的濃度，從如果你加培養(yǎng)基的太少，那么DMSO的濃度就會(huì)比較大，就會(huì)影響細(xì)胞生長，從以前的資料來看，DMSO的濃度在小于０.５%的時(shí)候?qū)σ话慵?xì)胞沒有什么影響，還有一個(gè)說法是１%。所以如果你的凍存的濃度是１０%DMSO的話那么加１０ml以上的培養(yǎng)基就恰HAO稀釋到了無害濃度。

換液周期：每周2-3次

CD18/HPAF Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：NB-9細(xì)胞、RL95-2細(xì)胞、Chinese Hamster Lung細(xì)胞

Hs281T Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代,每周換液２-３次。;生長特性：貼壁生長;形態(tài)特性：成纖維細(xì)胞;相關(guān)產(chǎn)品有：HBdSMC細(xì)胞、T9細(xì)胞、MC3T3-E1 Subclone 4細(xì)胞

AML-193 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代。３天內(nèi)可長滿。;生長特性：懸浮生長;形態(tài)特性：淋巴母細(xì)胞;相關(guān)產(chǎn)品有：SNU878細(xì)胞、KYSE 30細(xì)胞、Kelly細(xì)胞

Hela人宮頸癌復(fù)蘇細(xì)胞保種中心|帶STR證書

背景信息：HeLa是第一個(gè)來自人體組織經(jīng)連續(xù)培養(yǎng)獲得的非整倍體上皮樣細(xì)胞系，它由GeyGO等在１９５１年從３１歲女性黑人的宮頸癌組織建立。經(jīng)原始組織切片重新觀察，Jones等將其診斷為腺癌。已知該細(xì)胞系含有人乳頭狀瘤病毒HPV１８序列，需在２級(jí)生物安全防護(hù)臺(tái)操作。該細(xì)胞角蛋白陽性，p５３表達(dá)量較低，但表達(dá)正常水平的pRB（視網(wǎng)膜母細(xì)胞瘤抑制因子）。

公司細(xì)胞系形態(tài)漂亮、增殖倍數(shù)高、純度高、功能性強(qiáng)，細(xì)胞培養(yǎng)就跟養(yǎng)孩子一個(gè)樣。養(yǎng)孩子要喂奶，養(yǎng)細(xì)胞要加補(bǔ)液，都需要在前期補(bǔ)充足夠的營養(yǎng)，初始狀態(tài)的細(xì)胞或剛剛復(fù)蘇的細(xì)胞還要適量加入血清或細(xì)胞因子來幫助它們的存活增殖，如果營養(yǎng)物質(zhì)缺乏，細(xì)胞就會(huì)不生長甚至死亡。養(yǎng)孩子要從小培養(yǎng)學(xué)習(xí)，養(yǎng)細(xì)胞也得培養(yǎng)寶寶順利生下來，你會(huì)經(jīng)常撫摸他，給他看各種顏色，刺激他的五感。細(xì)胞也是一樣，分離后的細(xì)胞需要使用特定的細(xì)胞因子進(jìn)行活化、增殖。另外加入因子的種類、因子的濃度、加入時(shí)間、加入順序都會(huì)影響細(xì)胞最終的結(jié)果。養(yǎng)孩子最怕孩子生病，養(yǎng)細(xì)胞最怕被污染，平時(shí)你會(huì)仔細(xì)觀察寶寶是否嘔吐、是否突然哭鬧，猜測寶寶是否生病了。對于細(xì)胞，我們也需要時(shí)刻進(jìn)行觀察的，假如培養(yǎng)液渾濁(污染了)，則需要換液后加抗生素；假如細(xì)胞增殖不明顯，形態(tài)變差，則可能是因?yàn)闋I養(yǎng)不足了，對貼壁細(xì)胞可以消化后重新用新的培養(yǎng)基接種并加倍加入細(xì)胞因子含量；對懸浮細(xì)胞增殖能力不強(qiáng)的，則不著急補(bǔ)液，只是先補(bǔ)加血清、細(xì)胞因子看是否可以好轉(zhuǎn)。培養(yǎng)時(shí)還得全程在無菌的環(huán)境，一個(gè)小小的偏差，細(xì)胞就會(huì)死亡。

產(chǎn)品包裝：復(fù)蘇發(fā)貨：T25培養(yǎng)瓶(一瓶)或凍存發(fā)貨：1ml凍存管(兩支)

來源說明：細(xì)胞主要來源ATCC、ECACC、DSMZ、RIKEN等細(xì)胞庫

PLCPRF5 Cells;背景說明：該細(xì)胞系分泌乙肝病毒表面抗原（HBsAg）。 此細(xì)胞系原先被支原體污染，后用BM-cycline去除支原體;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：SCL-II細(xì)胞、QBC939細(xì)胞、L929(NCTC)細(xì)胞

CCD18Co Cells;背景說明：結(jié)腸；成纖維細(xì)胞；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HLE B-3細(xì)胞、NCI-H1385細(xì)胞、HBL 100細(xì)胞

Hs-940 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代，２-３天換液１次。;生長特性：貼壁生長;形態(tài)特性：成纖維細(xì)胞;相關(guān)產(chǎn)品有：UCLA RO-81-A-1細(xì)胞、SK-Hep1細(xì)胞、751-NA-15細(xì)胞

Nb2a Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：４傳代；２-３天換液１次;生長特性：貼壁生長;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：CEM clone 7細(xì)胞、PIGI細(xì)胞、Kato-III細(xì)胞

Hela人宮頸癌復(fù)蘇細(xì)胞保種中心|帶STR證書

物種來源：人源、鼠源等其它物種來源

形態(tài)特性：上皮細(xì)胞樣

其實(shí)絕大部分細(xì)胞消化的時(shí)候是只要用胰酶潤洗一遍即可，吸去胰酶后，殘留的那些無法計(jì)算體積的附著在細(xì)胞表面的微量胰酶在３７度一般不到２min足夠消化細(xì)胞(絕大部分１min不到)。對于這些細(xì)胞原則上不要用胰酶孵育細(xì)胞，連續(xù)這樣傳代，對細(xì)胞傷害很大。簡單的程序是PBS潤洗吸去，胰酶潤洗吸去，然后３７度消化；什么算是消化HAO了呢？不是細(xì)胞全部成間隔分布很離散的單個(gè)圓形才算消化HAO了，一般你肉眼觀察貼壁細(xì)胞層，只要能移動(dòng)了，多半呈沙壯移動(dòng)，其實(shí)已經(jīng)可以了，很多人喜歡把細(xì)胞消化或者吹打成完全分離細(xì)胞，這是沒有必要的。一般能移動(dòng)了，說明細(xì)胞與培養(yǎng)基質(zhì)材料的附著已經(jīng)消失了，細(xì)胞之間的附著也已經(jīng)消失了，細(xì)胞已經(jīng)獨(dú)立分布了(雖然沒有呈現(xiàn)很廣的離散分布)。這個(gè)時(shí)候應(yīng)該停止消化，不要等到看到鏡下所有細(xì)胞都分離得非常HAO，間隙很大，才停止。細(xì)胞就是完全成單個(gè)細(xì)胞懸，之后在貼壁的過程中仍然會(huì)聚集，這個(gè)是貼壁培養(yǎng)的細(xì)胞，尤其是腫瘤細(xì)胞的一個(gè)性，無論死活的細(xì)胞都是如此，你可以嘗試，準(zhǔn)備１００%的單個(gè)細(xì)胞懸，貼壁后觀察細(xì)胞，仍然是幾個(gè)幾個(gè)細(xì)胞聚集在一起。一些懸浮培養(yǎng)細(xì)胞也是如此，容易聚集，不要去嘗試過幾個(gè)小時(shí)就拿出來吹打成單細(xì)胞懸(不要笑，這個(gè)是初養(yǎng)懸浮細(xì)胞的人常犯的錯(cuò)誤，以為懸浮培養(yǎng)就是一個(gè)一個(gè)分開)。細(xì)胞只要能從基質(zhì)上脫離下來，這個(gè)時(shí)候即使是成片的(比如Calu-３細(xì)胞)，吹打不超過２０次后(一般１０次即可)，成小規(guī)模聚集(１０個(gè)細(xì)胞左右)，是正常的，不要試圖再去延長消化時(shí)間，或者像有的同學(xué)那樣吹打１h，等待單細(xì)胞懸出現(xiàn)。

PG-4 (S+L-) Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SB細(xì)胞、MCF7細(xì)胞、COC1/CDDP細(xì)胞

HEK 293T/17 Cells;背景說明：胚腎；５型腺病毒及SV４０轉(zhuǎn)化；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SKML-28細(xì)胞、FHs 74 Int細(xì)胞、BHT-101細(xì)胞

SAS Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１０^５ cells/６０mm dish;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：GA-10-Clone-4細(xì)胞、NPA細(xì)胞、H-650細(xì)胞

Mahlavu Cells;背景說明：肝癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Sp2/0-Ag14細(xì)胞、MB468細(xì)胞、HO-1-N-1細(xì)胞

U-118MG Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：PK-15細(xì)胞、293EBNA細(xì)胞、HPDEC細(xì)胞

NCI-BL1339 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：３-４天換液１次。;生長特性：懸浮生長;形態(tài)特性：淋巴母細(xì)胞樣　;相關(guān)產(chǎn)品有：Neuro-2a細(xì)胞、Tb 1-Lu細(xì)胞、NCTC1469細(xì)胞

H1963 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：每周換液２次。;生長特性：懸浮生長;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SK Col 1細(xì)胞、GA-10 clone 4細(xì)胞、MCF-7/ADR細(xì)胞

LICR-LON-HN6-R Cells;背景說明：舌鱗癌；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：751細(xì)胞、VM-CUB-1細(xì)胞、IGR.OV1細(xì)胞

MDAMB330 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Sarcoma OSteogenic-2細(xì)胞、OsA-CL細(xì)胞、MADISON LUNG TA-109細(xì)胞

MKN-45 Cells;背景說明：該細(xì)胞系由S Akiyama建立，源于一位３５歲患有印戒細(xì)胞癌的女性的胃淋巴結(jié)。;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁+懸浮;形態(tài)特性：淋巴母細(xì)胞;相關(guān)產(chǎn)品有：SHSY-5Y細(xì)胞、HPB/ALL細(xì)胞、MCF-7細(xì)胞

TE 32.T Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：４傳代，３-４天換液１次。;生長特性：貼壁生長;形態(tài)特性：梭型和大的多核細(xì)胞;相關(guān)產(chǎn)品有：SF 767細(xì)胞、WEHI-3B細(xì)胞、C1498細(xì)胞

2780CP Cells;背景說明：卵巢癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：KOPN8細(xì)胞、TFH細(xì)胞、CHP-100細(xì)胞

3T3-L1 Cells;背景說明：３T３-L１是從３T３細(xì)胞（Swissalbino）中經(jīng)克隆分離得到的連續(xù)傳代的亞系。該細(xì)胞從快速分裂到匯合和接觸性抑制狀態(tài)經(jīng)歷了前脂肪細(xì)胞到脂肪樣細(xì)胞的轉(zhuǎn)變。該細(xì)胞鼠痘病毒陰性；可產(chǎn)生甘油三酯，高濃度血清可增強(qiáng)細(xì)胞內(nèi)脂肪堆積。;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：成纖維細(xì)胞樣;相關(guān)產(chǎn)品有：NS1-Ag 4/1細(xì)胞、LTEP-a2細(xì)胞、CCD1112Sk細(xì)胞

DU_145 Cells;背景說明：DU １４５ 是從一位有３年淋巴細(xì)胞白血病史的前列腺癌患者的腦部轉(zhuǎn)移灶中建立的。該細(xì)胞系未檢測到激素敏感性，酸性酶陽性，單個(gè)的細(xì)胞可在軟瓊脂中形成集落。對此細(xì)胞和原始腫瘤的亞顯微結(jié)構(gòu)分析可見微絨毛、微絲、細(xì)胞橋粒、線粒體、發(fā)達(dá)的高爾基體和異質(zhì)溶酶體。該細(xì)胞不表達(dá)前列腺抗原。;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：ETCC-007細(xì)胞、FT-293細(xì)胞、RCC 7860細(xì)胞

TE32 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：４傳代，３-４天換液１次。;生長特性：貼壁生長;形態(tài)特性：梭型和大的多核細(xì)胞;相關(guān)產(chǎn)品有：NIH-3T3細(xì)胞、LC1-Sq細(xì)胞、MDA-MB-415細(xì)胞

T47D:A Cells;背景說明：浸潤性導(dǎo)管癌；胸腔積液轉(zhuǎn)移；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：PL-45細(xì)胞、FLC7細(xì)胞、OACP4 C細(xì)胞

207 Cells;背景說明：兒童急性髓系白血病;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：CHOS細(xì)胞、Panc-03.27細(xì)胞、HEC1-A細(xì)胞

Hela人宮頸癌復(fù)蘇細(xì)胞保種中心|帶STR證書

246G6 Cells(提供STR鑒定圖譜)

Abcam HeLa PRKCI KO Cells(提供STR鑒定圖譜)

AG24313 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line RRH327 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line XH348 Cells(提供STR鑒定圖譜)

C17ABR Cells(提供STR鑒定圖譜)

D551-RiPS-1.2 Cells(提供STR鑒定圖譜)

DA06208 Cells(提供STR鑒定圖譜)

GM00740 Cells(提供STR鑒定圖譜)

SW-480 Cells;背景說明：SW４８０源自一位５１歲白人男性患者的原位直腸腺癌，而SW６２０源自同一病人一年后的淋巴結(jié)轉(zhuǎn)移灶。該細(xì)胞CSAp和直腸抗原３陰性；角蛋白陽性；p５３基因第２７３位密碼子的G→A突變引起Arg→His替代，３０９位密碼子的C→T突變導(dǎo)致Pro→Ser替代；細(xì)胞p５３蛋白表達(dá)水平升高；癌基因c-myc、K-ras、H-ras、N-ras、myb、sis和fos的表達(dá)呈陽性；未檢測到癌基因N-myc的表達(dá)；不表達(dá)Matrilysin（一種與腫瘤侵襲相關(guān)的金屬蛋白酶）。;傳代方法：１：２傳代，１-２天換液一次;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：NCI-H78細(xì)胞、MSB-1細(xì)胞、BALL-1細(xì)胞

U266 B1 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３傳代,２-３天傳一代;生長特性：懸浮生長 ;形態(tài)特性：淋巴母細(xì)胞樣;相關(guān)產(chǎn)品有：NCIH727細(xì)胞、NHA細(xì)胞、H920細(xì)胞

P3J HR-1 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：每２-３天換液;生長特性：懸浮生長 ;形態(tài)特性：淋巴母細(xì)胞樣;相關(guān)產(chǎn)品有：GM02219C細(xì)胞、NCI.H23細(xì)胞、MDA-MB-231-luc細(xì)胞

624 MEL Cells;背景說明：黑色素瘤；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SNUC1細(xì)胞、CCD-841CoN細(xì)胞、COLO-684細(xì)胞

MUTZ-1 Cells;背景說明：骨髓增生異常綜合征；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SKM1細(xì)胞、HEK293-EBNA細(xì)胞、HIT-T15細(xì)胞

NCI-H446 Cells;背景說明：該細(xì)胞是１９８２年由CarneyD和GazdarAF等從一位小細(xì)胞肺癌患者的胸腔積液中建立的。細(xì)胞的原始形態(tài)并不具有小細(xì)胞肺癌特征。這個(gè)細(xì)胞株是小細(xì)胞肺癌的生化和形態(tài)學(xué)上的變種，表達(dá)神經(jīng)元特有的烯醇酶和腦型肌酸激酶同工酶；左旋多巴脫羧酶、蠶素、抗利尿激素、催產(chǎn)素或胃泌激素釋放肽未達(dá)到可檢測水平。與正常細(xì)胞相比，該細(xì)胞c-mycDNA序列擴(kuò)增約２０倍，RNA增加１５倍。最初傳代培養(yǎng)基用含有５%FBS的RPMI１６４０，另外添加１０nM化可的松、０.００５mg/ml胰島素、０.０１mg/ml轉(zhuǎn)鐵;傳代方法：１：２傳代;生長特性：貼壁/懸浮生長，混合;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：WM 451-Lu細(xì)胞、TALL1細(xì)胞、H-226細(xì)胞

2F9-C9 Cells(提供STR鑒定圖譜)

TE-3A Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：COLO 741細(xì)胞、GM06141B細(xì)胞、SuperTube細(xì)胞

CNE2Z Cells;背景說明：鼻咽癌;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：LOU-NH-91細(xì)胞、COS-1細(xì)胞、CNE細(xì)胞

alpha-TC1.6 Cells;背景說明：胰島素瘤；a細(xì)胞；C５７BL/６xDBA/２;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Line 522細(xì)胞、MV 4;11細(xì)胞、Leydig細(xì)胞

B16F1 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：870細(xì)胞、IPLB-Sf21細(xì)胞、BALB/3T3 cl. A31細(xì)胞

A375-S2 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：Roswell Park Memorial Institute 7666細(xì)胞、SU-DHL-16細(xì)胞、C8166細(xì)胞

H69/P Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２—１：４傳代，每周換液２次;生長特性：懸浮生長，聚團(tuán);形態(tài)特性：聚團(tuán)懸浮;相關(guān)產(chǎn)品有：Mo 59J細(xì)胞、SNU-1040細(xì)胞、HFT-8810細(xì)胞

TGW-I-nu Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：神經(jīng)元細(xì)胞;相關(guān)產(chǎn)品有：NOK細(xì)胞、N1E-115細(xì)胞、MD Anderson-Metastatic Breast-157細(xì)胞

NCI-H1836 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：每周換液２-３次。;生長特性：懸浮生長;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：GRSL細(xì)胞、WM 266-4細(xì)胞、Jurkat 77細(xì)胞

GM10144 Cells(提供STR鑒定圖譜)

HAP1 C1orf115 (-) 2 Cells(提供STR鑒定圖譜)

RC-K8 Cells;背景說明：彌漫大B淋巴瘤；腹腔轉(zhuǎn)移；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HEK293-FT細(xì)胞、Molm 14細(xì)胞、KLN205細(xì)胞

SCC-25 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３-１：１０傳代，２-３天換液１次。;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：ZR75-1細(xì)胞、HUT 28細(xì)胞、RPMI #1846細(xì)胞

aNK Cells;背景說明：NK細(xì)胞；淋巴瘤；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：OVCA8細(xì)胞、BNL 1ME A.7R.1細(xì)胞、NALM-6-M1細(xì)胞

HCCLM3 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：HAEC細(xì)胞、Panc_03_27細(xì)胞、EB-3細(xì)胞

Biopsy xenograft of Pancreatic Carcinoma line-3 Cells;背景說明：這個(gè)細(xì)胞株不表達(dá)囊腫性纖維化跨膜電導(dǎo)調(diào)節(jié)子(CFTR)。CFTR陽性的細(xì)胞株是Capan-１(ATCCHTB-７９)。;傳代方法：消化５-１０分鐘。１：２。３天內(nèi)可長滿。;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：FU-97細(xì)胞、OCM-1細(xì)胞、WM-451Lu細(xì)胞

HEMCSS Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：４-１：８傳代；每周換液３次。;生長特性：貼壁生長;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：STTG1細(xì)胞、SKCO 1細(xì)胞、RL95細(xì)胞

Y3-Ag 1.2.3 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：0V-1063細(xì)胞、DU_145細(xì)胞、ECC-10細(xì)胞

KNS-81 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：H-1876細(xì)胞、RS1細(xì)胞、BRL 3A細(xì)胞

HG03584 Cells(提供STR鑒定圖譜)

IDG-HEK293T-PANX2-V5-OE Cells(提供STR鑒定圖譜)

LR-274 Cells(提供STR鑒定圖譜)

NCI-HPN-M1C Colon Cells(提供STR鑒定圖譜)

PathHunter U2OS RXRalpha Protein Interaction Cells(提供STR鑒定圖譜)

Ubigene H9c2(2-1) Hif1an KO Cells(提供STR鑒定圖譜)

Vero-SCARB2 Cells(提供STR鑒定圖譜)

HFL-I Cells(提供STR鑒定圖譜)

HES [Human embryonic skin fibroblast] Cells;背景說明：皮膚；成纖維 Cells;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：QSG7701細(xì)胞、HOP62細(xì)胞、THPI細(xì)胞

Scott Cells;背景說明：胚胎；自發(fā)永生;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：GOS3細(xì)胞、SCC 4細(xì)胞、SW1116細(xì)胞

UMUC-14 Cells;背景說明：腎癌；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HCAEC細(xì)胞、NS-20Y細(xì)胞、CTLL2細(xì)胞

LNT-229 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：４-１：６傳代；每周換液２-３次;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：H1435細(xì)胞、MAVER-1細(xì)胞、C-33A細(xì)胞

VP303 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Huh-7細(xì)胞、COLO 205細(xì)胞、MOLP-8細(xì)胞

MC 3T3-E1 Cells;背景說明：該細(xì)胞有多個(gè)亞克隆，可以作為體外研究成骨細(xì)胞分化的良好模型，尤其是ECM信號(hào)通路的作用。;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：成纖維細(xì)胞樣;相關(guān)產(chǎn)品有：SUNE1細(xì)胞、WBF344細(xì)胞、OE19細(xì)胞

BHK Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代，每周換液１-２次。;生長特性：貼壁生長;形態(tài)特性：成纖維細(xì)胞樣;相關(guān)產(chǎn)品有：TEC細(xì)胞、I90細(xì)胞、H2085細(xì)胞

Pan02 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長　;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：OVCAR.5細(xì)胞、JTC-28細(xì)胞、EHEB細(xì)胞

C28/I2 Cells;背景說明：軟骨；SV４０轉(zhuǎn)化；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：CHO/dhFr-細(xì)胞、Hos TE-85細(xì)胞、526 mel細(xì)胞

Panc4.03 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：RMG-1細(xì)胞、EB2細(xì)胞、Melanoma 14細(xì)胞

MC 3T3-E1 Cells;背景說明：該細(xì)胞有多個(gè)亞克隆，可以作為體外研究成骨細(xì)胞分化的良好模型，尤其是ECM信號(hào)通路的作用。;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：成纖維細(xì)胞樣;相關(guān)產(chǎn)品有：SUNE1細(xì)胞、WBF344細(xì)胞、OE19細(xì)胞

MAVER1 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３-１：５傳代；２-３天換液１次。;生長特性：懸浮生長;形態(tài)特性：淋巴母細(xì)胞;相關(guān)產(chǎn)品有：SNU-761細(xì)胞、HuNS1細(xì)胞、FF-WT-BJ細(xì)胞

ELD-1 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SKNEP-1細(xì)胞、22Rv-1細(xì)胞、BT-483細(xì)胞

BNL-CL.2 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長　;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：NW-MEL-38細(xì)胞、HSF細(xì)胞、P31-FUJ細(xì)胞

Karpas422 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：CAL 12細(xì)胞、Hepa 1-6細(xì)胞、W133細(xì)胞

SC [Human contaminated U-937] Cells(提供STR鑒定圖譜)

U-138-MG Cells;背景說明：星形細(xì)胞瘤；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SK-GT-2細(xì)胞、HNSC細(xì)胞、RIN-m5F細(xì)胞

Hs888 Lu Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長　;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：NE-4C細(xì)胞、NTERA-2 cl.D1細(xì)胞、Ca9-22細(xì)胞

OCI AML3 Cells;背景說明：急性髓系白血??；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SW 839細(xì)胞、MOLP-8細(xì)胞、OVISE細(xì)胞

BCaP-37 Cells;背景說明：源自一位４８歲女性乳癌患者。;傳代方法：消化３-５分鐘，１：２,３天內(nèi)可長滿;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：HCT-FET細(xì)胞、High Five細(xì)胞、H22-H8D8細(xì)胞

RAMSCs Cells;背景說明：脂肪間充質(zhì)干 Cells;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：H920細(xì)胞、DHL-6細(xì)胞、A3細(xì)胞

MCA-38 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：MILE SVEN 1細(xì)胞、MOLT 3細(xì)胞、OCI Ly10細(xì)胞

HCC-9724 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：LN299細(xì)胞、L-6 myoblast細(xì)胞、697細(xì)胞

293 F Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長；懸浮生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：Huh-7.5.1細(xì)胞、RS4-11細(xì)胞、U87細(xì)胞

UACC-812 Cells;背景說明：該細(xì)胞是由Liebovitz A等于１９８６年從一名４３歲的白人女性乳腺導(dǎo)管癌患者的乳腺切除腫瘤組織中分離建立的；手術(shù)前該病人曾接受過廣泛的化療。該細(xì)胞HER-２/neu癌基因序列有１５倍的擴(kuò)增；雌激素受體ER、孕激素受體PR和糖蛋白P陰性。;傳代方法：１：３傳代；５-７天１次?！?生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：HT144-mel細(xì)胞、CL 1-5細(xì)胞、H69C細(xì)胞

A-2780 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：H9c2細(xì)胞、TNC-1B12B4細(xì)胞、FU-OV-1細(xì)胞

PCI-SG231 Cells;背景說明：肝內(nèi)膽管癌；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HT1376細(xì)胞、HLMVEC細(xì)胞、Fao細(xì)胞

SKNFI Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：４傳代，每周換液２次;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：Acanthosis Nigricans 3rd attempt-CArcinoma細(xì)胞、CAL-12T細(xì)胞、NCI H295R細(xì)胞

A 375 Cells;背景說明：A３７５源自一位５４歲女性，是Giard DJ等人建立的一系列細(xì)胞株中的一株。該細(xì)胞可在免疫抑制小鼠上成瘤，在瓊脂上形成克隆。;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：LAPC4細(xì)胞、SCC25細(xì)胞、H-1651細(xì)胞

GT1-1 Cells;背景說明：GT１-１為GT１細(xì)胞系的亞克隆，GT１來源于穩(wěn)定表達(dá)SV４０大T抗原的轉(zhuǎn)基因小鼠產(chǎn)生的可以分泌促性腺激素釋放激素LHRH的腫瘤。GT１-１細(xì)胞可以表達(dá)pro-LHRHmRNA，并向培養(yǎng)基中分泌LHRH樣的免疫反應(yīng)性的物質(zhì)。;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：CPAE細(xì)胞、UPCI-SCC090細(xì)胞、Roswell Park Memorial Institute 7666細(xì)胞

Hela人宮頸癌復(fù)蘇細(xì)胞保種中心|帶STR證書

BayGenomics ES cell line RRJ519 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line XK518 Cells(提供STR鑒定圖譜)

FW14-14 Cells(提供STR鑒定圖譜)

NQ6.24.2 Cells(提供STR鑒定圖譜)

XF11.4C4 Cells(提供STR鑒定圖譜)

MCF7-parkin clone 11 Cells(提供STR鑒定圖譜)

" "PubMed=13261081

Moore A.E., Sabachewsky L., Toolan H.W.

Culture characteristics of four permanent lines of human cancer cells.

Cancer Res. 15:598-602(1955)

PubMed=16589695; DOI=10.1073/pnas.41.7.432; PMCID=PMC528114

Puck T.T., Marcus P.I.

A rapid method for viable cell titration and clone production with HeLa cells in tissue culture: the use of X-irradiated cells to supply conditioning factors.

Proc. Natl. Acad. Sci. U.S.A. 41:432-437(1955)

PubMed=14031339

Katzberg A.A.

The effect of space flights on living human cells aboard Discoverer XVIII.

Tech. Doc. Rep. SAMTDR USAF Sch. Aerosp. Med. 62:43.1-43.4(1962)

PubMed=14185313; DOI=10.1126/science.146.3641.241

Cell Culture Collection Committee

Animal cell strains. The Cell Culture Collection Committee has assembled and certified 23 strains of animal cells.

Science 146:241-243(1964)

PubMed=5668122; DOI=10.3181/00379727-128-33119

Peterson W.D. Jr., Stulberg C.S., Swanborg N.K., Robinson A.R.

Glucose-6-phosphate dehydrogenase isoenzymes in human cell cultures determined by sucrose-agar gel and cellulose acetate zymograms.

Proc. Soc. Exp. Biol. Med. 128:772-776(1968)

DOI=10.1007/BF02618370

Stulberg C.S., Coriell L.L., Kniazeff A.J., Shannon J.E.

The animal cell culture collection.

In Vitro 5:1-16(1970)

PubMed=4942173; DOI=10.1097/00006250-197112000-00028

Jones H.W. Jr., McKusick V.A., Harper P.S., Wuu K.-D.

George Otto Gey (1899-1970). The HeLa cell and a reappraisal of its origin.

Obstet. Gynecol. 38:945-949(1971)

DOI=10.1007/978-1-4757-1647-4_13

Biedler J.L.

Chromosome abnormalities in human tumor cells in culture.

(In book chapter) Human tumor cells in vitro; Fogh J. (eds.); pp.359-394; Springer; New York; USA (1975)

PubMed=1246620; DOI=10.1126/science.1246620

Hsu S.H., Schacter B.Z., Delaney N.L., Miller T.B., McKusick V.A., Kennett R.H., Bodmer J.G., Young D., Bodmer W.F.

Genetic characteristics of the HeLa cell.

Science 191:392-394(1976)

PubMed=77569; DOI=10.1111/j.1399-0039.1978.tb01259.x

Espmark J.A., Ahlqvist-Roth L., Sarne L., Persson A.

Tissue typing of cells in culture. III. HLA antigens of established human cell lines. Attempts at typing by the mixed hemadsorption technique.

Tissue Antigens 11:279-286(1978)

PubMed=6256643; DOI=10.1038/288724a0

Day R.S. 3rd, Ziolkowski C.H.J., Scudiero D.A., Meyer S.A., Lubiniecki A.S., Girardi A.J., Galloway S.M., Bynum G.D.

Defective repair of alkylated DNA by human tumour and SV40-transformed human cell strains.

Nature 288:724-727(1980)

PubMed=6935474; DOI=10.1093/jnci/66.2.239

Wright W.C., Daniels W.P., Fogh J.

Distinction of seventy-one cultured human tumor cell lines by polymorphic enzyme analysis.

J. Natl. Cancer Inst. 66:239-247(1981)

PubMed=6358339; DOI=10.1093/jhmas/38.4.415

Brown R.W., Henderson J.H.M.

The mass production and distribution of HeLa cells at Tuskegee Institute, 1953-55.

J. Hist. Med. Allied Sci. 38:415-431(1983)

PubMed=6401685; DOI=10.1007/BF02617989

Halton D.M., Peterson W.D. Jr., Hukku B.

Cell culture quality control by rapid isoenzymatic characterization.

In Vitro 19:16-24(1983)

PubMed=6825208; DOI=10.1093/carcin/4.2.199

Yarosh D.B., Foote R.S., Mitra S., Day R.S. 3rd

Repair of O6-methylguanine in DNA by demethylation is lacking in Mer- human tumor cell strains.

Carcinogenesis 4:199-205(1983)

PubMed=2983228; DOI=10.1038/314111a0

Schwarz E., Freese U.-K., Gissmann L., Mayer W., Roggenbuck B., Stremlau A., zur Hausen H.

Structure and transcription of human papillomavirus sequences in cervical carcinoma cells.

Nature 314:111-114(1985)

PubMed=2990217; PMCID=PMC1888002

Yee C., Krishnan-Hewlett I., Baker C.C., Schlegel R., Howley P.M.

Presence and expression of human papillomavirus sequences in human cervical carcinoma cell lines.

Am. J. Pathol. 119:361-366(1985)

CLPUB00262

Gold M.

A conspiracy of cells. One woman's immortal legacy and the medical scandal it caused.

(In book) ISBN 9780887060991; pp.1-171; State University of New York Press; Albany; USA (1986)

PubMed=3518877; DOI=10.3109/07357908609038260

Fogh J.

Human tumor lines for cancer research.

Cancer Invest. 4:157-184(1986)

PubMed=3028716; DOI=10.1159/000132342

Popescu N.C., DiPaolo J.A., Amsbaugh S.C.

Integration sites of human papillomavirus 18 DNA sequences on HeLa cell chromosomes.

Cytogenet. Cell Genet. 44:58-62(1987)

PubMed=3180844; DOI=10.1159/000132579

Chen T.-R.

Re-evaluation of HeLa, HeLa S3, and HEp-2 karyotypes.

Cytogenet. Cell Genet. 48:19-24(1988)

PubMed=3371749; DOI=10.1016/0090-8258(88)90029-7

Grenman S.E., Shapira A., Carey T.E.

In vitro response of cervical cancer cell lines CaSki, HeLa, and ME-180 to the antiestrogen tamoxifen.

Gynecol. Oncol. 30:228-238(1988)

PubMed=1522048; DOI=10.1007/BF02634140

Kataoka E., Honma M., Ohnishi K., Sofuni T., Mizusawa H.

Application of highly polymorphic DNA markers to the identification of HeLa cell sublines.

In Vitro Cell. Dev. Biol. Anim. 28:553-556(1992)

PubMed=8380785; DOI=10.1006/gyno.1993.1016

Iwasaka T., Oh-uchida M., Matsuo N., Yokoyama M., Fukuda K., Hara K., Fukuyama K., Hori K., Sugimori H.

Correlation between HPV positivity and state of the p53 gene in cervical carcinoma cell lines.

Gynecol. Oncol. 48:104-109(1993)

PubMed=9892199

Macville M.V.E., Schrock E., Padilla-Nash H.M., Keck C., Ghadimi B.M., Zimonjic D.B., Popescu N.C., Ried T.

Comprehensive and definitive molecular cytogenetic characterization of HeLa cells by spectral karyotyping.

Cancer Res. 59:141-150(1999)

PubMed=10423141; DOI=10.1099/0022-1317-80-7-1725

Meissner J.D.

Nucleotide sequences and further characterization of human papillomavirus DNA present in the CaSki, SiHa and HeLa cervical carcinoma cell lines.

J. Gen. Virol. 80:1725-1733(1999)

PubMed=11416159; DOI=10.1073/pnas.121616198; PMCID=PMC35459

Masters J.R.W., Thomson J.A., Daly-Burns B., Reid Y.A., Dirks W.G., Packer P., Toji L.H., Ohno T., Tanabe H., Arlett C.F., Kelland L.R., Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.

Short tandem repeat profiling provides an international reference standard for human cell lines.

Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001)

PubMed=11668190; DOI=10.1177/002215540104901105

Quentmeier H., Osborn M., Reinhardt J., Zaborski M., Drexler H.G.

Immunocytochemical analysis of cell lines derived from solid tumors.

J. Histochem. Cytochem. 49:1369-1378(2001)

PubMed=12001993; DOI=10.1038/nrc775

Masters J.R.W.

HeLa cells 50 years on: the good, the bad and the ugly.

Nat. Rev. Cancer 2:315-319(2002)

PubMed=12793746; DOI=10.1269/jrr.43.s133

Ohnishi T., Ohnishi K., Takahashi A., Taniguchi Y., Sato M., Nakano T., Nagaoka S.

Detection of DNA damage induced by space radiation in Mir and space shuttle.

J. Radiat. Res. 43 Suppl. 1:S133-S136(2002)

PubMed=12661003; DOI=10.1002/gcc.10196

Seitz S., Wassmuth P., Plaschke J., Schackert H.K., Karsten U., Santibanez-Koref M.F., Schlag P.M., Scherneck S.

Identification of microsatellite instability and mismatch repair gene mutations in breast cancer cell lines.

Genes Chromosomes Cancer 37:29-35(2003)

PubMed=15302935; DOI=10.1073/pnas.0404720101; PMCID=PMC514446

Beausoleil S.A., Jedrychowski M.P., Schwartz D., Elias J.E., Villen J., Li J.-X., Cohn M.A., Cantley L.C., Gygi S.P.

Large-scale characterization of HeLa cell nuclear phosphoproteins.

Proc. Natl. Acad. Sci. U.S.A. 101:12130-12135(2004)

PubMed=15531914; DOI=10.1038/sj.onc.1208235

Baldus S.E., Schwarz E., Lohrey C., Zapatka M., Landsberg S., Hahn S.A., Schmidt D., Dienes H.-P., Schmiegel W.H., Schwarte-Waldhoff I.

Smad4 deficiency in cervical carcinoma cells.

Oncogene 24:810-819(2005)

PubMed=15901131; DOI=10.1016/j.prp.2005.01.002

Murai Y., Hayashi S., Takahashi H., Tsuneyama K., Takano Y.

Correlation between DNA alterations and p53 and p16 protein expression in cancer cell lines.

Pathol. Res. Pract. 201:109-115(2005)

PubMed=17311676; DOI=10.1186/1471-2164-8-53; PMCID=PMC1805756

Kloth J.N., Oosting J., van Wezel T., Szuhai K., Knijnenburg J., Gorter A., Kenter G.G., Fleuren G.J., Jordanova E.S.

Combined array-comparative genomic hybridization and single-nucleotide polymorphism-loss of heterozygosity analysis reveals complex genetic alterations in cervical cancer.

BMC Genomics 8:53.1-53.13(2007)

PubMed=19450234; DOI=10.2144/000113089; PMCID=PMC2696096

Rahbari R., Sheahan T., Modes V., Collier P., Macfarlane C.M., Badge R.M.

A novel L1 retrotransposon marker for HeLa cell line identification.

BioTechniques 46:277-284(2009)

PubMed=19722756; DOI=10.5858/133.9.1463

Lucey B.P., Nelson-Rees W.A., Hutchins G.M.

Henrietta Lacks, HeLa cells, and cell culture contamination.

Arch. Pathol. Lab. Med. 133:1463-1467(2009)

CLPUB00377

Skloot R.L.

The immortal life of Henrietta Lacks.

(In book) ISBN 9781400052172; pp.1-400; Random House; New York; USA (2010)

CLPUB00468

Javitt G.H.

Why not take all of me? Reflections on the immortal life of Henrietta Lacks and the status of participants in research using human specimens.

Minn. J. Law Sci. Technol. 11:713-755(2010)

PubMed=19941903; DOI=10.1016/j.jviromet.2009.11.022

Karger A., Bettin B., Lenk M., Mettenleiter T.C.

Rapid characterisation of cell cultures by matrix-assisted laser desorption/ionisation mass spectrometric typing.

J. Virol. Methods 164:116-121(2010)

PubMed=21269460; DOI=10.1186/1752-0509-5-17; PMCID=PMC3039570

Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Burckstummer T., Bennett K.L., Superti-Furga G., Colinge J.

Initial characterization of the human central proteome.

BMC Syst. Biol. 5:17.1-17.13(2011)

PubMed=22068331; DOI=10.1038/msb.2011.81; PMCID=PMC3261714

Nagaraj N., Wisniewski J.R., Geiger T., Cox J., Kircher M., Kelso J., Paabo S., Mann M.

Deep proteome and transcriptome mapping of a human cancer cell line.

Mol. Syst. Biol. 7:548-548(2011)

PubMed=21937730; DOI=10.1074/mcp.M111.011429; PMCID=PMC3316722

Boisvert F.-M., Ahmad Y., Gierlinski M., Charriere F., Lamont D., Scott M., Barton G., Lamond A.I.

A quantitative spatial proteomics analysis of proteome turnover in human cells.

Mol. Cell. Proteomics 11:M111.011429-M111.011429(2012)

PubMed=22278370; DOI=10.1074/mcp.M111.014050; PMCID=PMC3316730

Geiger T., Wehner A., Schaab C., Cox J., Mann M.

Comparative proteomic analysis of eleven common cell lines reveals ubiquitous but varying expression of most proteins.

Mol. Cell. Proteomics 11:M111.014050-M111.014050(2012)

PubMed=22412903; DOI=10.1371/journal.pone.0032667; PMCID=PMC3296745

Vazquez-Mena O., Medina-Martinez I., Juarez-Torres E., Barron V., Espinosa A., Villegas-Sepulveda N., Gomez-Laguna L., Nieto-Martinez K., Orozco L., Roman-Bassaure E., Munoz Cortez S., Borges Ibanez M., Venegas-Vega C.A., Guardado-Estrada M., Rangel-Lopez A., Kofman S., Berumen J.

Amplified genes may be overexpressed, unchanged, or downregulated in cervical cancer cell lines.

PLoS ONE 7:E32667-E32667(2012)

CLPUB00507

Pultarova T.

HeLa cells: immortal space travellers.

Space Saf. Mag. 7:10-12(2013)

PubMed=23205564; DOI=10.1021/pr300859k

Malerod H., Graham R.L.J., Sweredoski M.J., Hess S.

Comprehensive profiling of N-linked glycosylation sites in HeLa cells using hydrazide enrichment.

J. Proteome Res. 12:248-259(2013)

PubMed=23336012; DOI=10.1371/journal.pone.0054672; PMCID=PMC3545996

Horvat T., Dezeljin M., Redzic I., Barisic D., Herak Bosnar M., Lauc G., Zoldos V.

Reversibility of membrane N-glycome of HeLa cells upon treatment with epigenetic inhibitors.

PLoS ONE 8:E54672-E54672(2013)

PubMed=23925224; DOI=10.1038/500141a; PMCID=PMC5101952

Hudson K.L., Collins F.S.

Biospecimen policy: family matters.

Nature 500:141-142(2013)

PubMed=23925245; DOI=10.1038/nature12064; PMCID=PMC3740412

Adey A.C., Burton J.N., Kitzman J.O., Hiatt J.B., Lewis A.P., Martin B.K., Qiu R.-L., Lee C., Shendure J.

The haplotype-resolved genome and epigenome of the aneuploid HeLa cancer cell line.

Nature 500:207-211(2013)

PubMed=24134916; DOI=10.1186/1755-8166-6-44; PMCID=PMC3879223

McCormack A., Fan J.-L., Duesberg M., Bloomfield M., Fiala C., Duesberg P.H.

Individual karyotypes at the origins of cervical carcinomas.

Mol. Cytogenet. 6:44.1-44.23(2013)

PubMed=24618588; DOI=10.1371/journal.pone.0091433; PMCID=PMC3950186

Chernobrovkin A.L., Zubarev R.A.

Detection of viral proteins in human cells lines by xeno-proteomics: elimination of the last valid excuse for not testing every cellular proteome dataset for viral proteins.

PLoS ONE 9:E91433-E91433(2014)

PubMed=24696503; DOI=10.1074/mcp.M113.035170; PMCID=PMC4047476

Guo X.-F., Trudgian D.C., Lemoff A., Yadavalli S., Mirzaei H.

Confetti: a multiprotease map of the HeLa proteome for comprehensive proteomics.

Mol. Cell. Proteomics 13:1573-1584(2014)

PubMed=24908793

Gilgenkrantz S.

Sixty years of HeLa cell cultures.

Hist. Sci. Med. 48:139-144(2014)

PubMed=25960936; DOI=10.4161/21624011.2014.954893; PMCID=PMC4355981

Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.

A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.

OncoImmunology 3:e954893.1-e954893.12(2014)

CLPUB00376

Verspaget C.J.

Unruly bodies: monstrous readings of biotechnology.

Thesis PhD (2015); Curtin University; Perth; Australia

PubMed=25485619; DOI=10.1038/nbt.3080

Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.

A comprehensive transcriptional portrait of human cancer cell lines.

Nat. Biotechnol. 33:306-312(2015)

PubMed=25807930; DOI=10.1002/anie.201500342; PMCID=PMC4471546

Broncel M., Serwa R.A., Ciepla P., Krause E., Dallman M.J., Magee A.I., Tate E.W.

Multifunctional reagents for quantitative proteome-wide analysis of protein modification in human cells and dynamic profiling of protein lipidation during vertebrate development.

Angew. Chem. Int. Ed. Engl. 54:5948-5951(2015)

PubMed=25877200; DOI=10.1038/nature14397

Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.

A resource for cell line authentication, annotation and quality control.

Nature 520:307-311(2015)

PubMed=25894527; DOI=10.1371/journal.pone.0121314; PMCID=PMC4404347

Bausch-Fluck D., Hofmann A., Bock T., Frei A.P., Cerciello F., Jacobs A., Moest H., Omasits U., Gundry R.L., Yoon C., Schiess R., Schmidt A., Mirkowska P., Hartlova A.S., Van Eyk J.E., Bourquin J.-P., Aebersold R., Boheler K.R., Zandstra P.W., Wollscheid B.

A mass spectrometric-derived cell surface protein atlas.

PLoS ONE 10:E0121314-E0121314(2015)

PubMed=26554430; DOI=10.1021/acs.analchem.5b03639

Dimayacyac-Esleta B.R.T., Tsai C.-F., Kitata R.B., Lin P.-Y., Choong W.-K., Lin T.-D., Wang Y.-T., Weng S.-H., Yang P.-C., Arco S.D., Sung T.-Y., Chen Y.-J.

Rapid high-pH reverse phase stagetip for sensitive small-scale membrane proteomic profiling.

Anal. Chem. 87:12016-12023(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878

Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Genome Med. 7:118.1-118.7(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469

Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Miroo T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

A landscape of pharmacogenomic interactions in cancer.

Cell 166:740-754(2016)

PubMed=28078501; DOI=10.1007/s11626-016-0128-8

Ambrose C.T.

The Tissue Culture Laboratory of Dr. George Otto Gey 60 yrs ago as recalled by a former student.

In Vitro Cell. Dev. Biol. Anim. 53:467-473(2017)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076

Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.

Characterization of human cancer cell lines by reverse-phase protein arrays.

Cancer Cell 31:225-239(2017)

PubMed=28261610; DOI=10.1155/2017/4180703; PMCID=PMC5316418

Kontostathi G., Zoidakis J., Makridakis M., Lygirou V., Mermelekas G., Papadopoulos T., Vougas K., Vlamis-Gardikas A., Drakakis P., Loutradis D., Vlahou A., Anagnou N.P., Pappa K.I.

Cervical cancer cell line secretome highlights the roles of transforming growth factor-beta-induced protein ig-h3, peroxiredoxin-2, and NRF2 on cervical carcinogenesis.

BioMed Res. Int. 2017:4180703.1-4180703.15(2017)

PubMed=28601559; DOI=10.1016/j.cels.2017.05.009; PMCID=PMC5493283

Bekker-Jensen D.B., Kelstrup C.D., Batth T.S., Larsen S.C., Haldrup C., Bramsen J.B., Sorensen K.D., Hoyer S., Orntoft T.F., Lindbjerg Andersen C., Nielsen M.L., Olsen J.V.

An optimized shotgun strategy for the rapid generation of comprehensive human proteomes.

Cell Syst. 4:587-599.e4(2017)

PubMed=29156801; DOI=10.18632/oncotarget.21174; PMCID=PMC5689691

Kalu N.N., Mazumdar T., Peng S.-H., Shen L., Sambandam V., Rao X.-Y., Xi Y.-X., Li L.-R., Qi Y., Gleber-Netto F.O., Patel A., Wang J., Frederick M.J., Myers J.N., Pickering C.R., Johnson F.M.

Genomic characterization of human papillomavirus-positive and -negative human squamous cell cancer cell lines.

Oncotarget 8:86369-86383(2017)

PubMed=30175587; DOI=10.1021/acs.jproteome.8b00392

Robin T., Bairoch A., Muller M., Lisacek F., Lane L.

Large-scale reanalysis of publicly available HeLa cell proteomics data in the context of the Human Proteome Project.

J. Proteome Res. 17:4160-4170(2018)

PubMed=30778230; DOI=10.1038/s41587-019-0037-y

Liu Y.-S., Mi Y., Mueller T., Kreibich S., Williams E.G., Van Drogen A., Borel C., Frank M., Germain P.-L., Bludau I., Mehnert M., Seifert M., Emmenlauer M., Sorg I., Bezrukov F., Sloan-Bena F., Zhou H., Dehio C., Testa G., Saez-Rodriguez J., Antonarakis S.E., Hardt W.-D., Aebersold R.

Multi-omic measurements of heterogeneity in HeLa cells across laboratories.

Nat. Biotechnol. 37:314-322(2019)

PubMed=30787054; DOI=10.1158/1055-9965.EPI-18-1132; PMCID=PMC6548687

Hooker S.E. Jr., Woods-Burnham L., Bathina M., Lloyd S., Gorjala P., Mitra R., Nonn L., Kimbro K.S., Kittles R.A.

Genetic ancestry analysis reveals misclassification of commonly used cancer cell lines.

Cancer Epidemiol. Biomarkers Prev. 28:1003-1009(2019)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103

Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Nature 569:503-508(2019)

PubMed=31433507; DOI=10.15252/embj.2018100847; PMCID=PMC6826212

Hardman G., Perkins S., Brownridge P.J., Clarke C.J., Byrne D.P., Campbell A.E., Kalyuzhnyy A., Myall A., Eyers P.A., Jones A.R., Eyers C.E.

Strong anion exchange-mediated phosphoproteomics reveals extensive human non-canonical phosphorylation.

EMBO J. 38:e100847.1-e100847.22(2019)

PubMed=31790455; DOI=10.1371/journal.pone.0225466; PMCID=PMC6886862

Hu W.-E., Zhang X., Guo Q.-F., Yang J.-W., Yang Y., Wei S.-C., Su X.-D.

HeLa-CCL2 cell heterogeneity studied by single-cell DNA and RNA sequencing.

PLoS ONE 14:E0225466-E0225466(2019)

PubMed=33389257; DOI=10.1007/s10096-020-04106-0; PMCID=PMC7778494

Wurtz N., Penant G., Jardot P., Duclos N., La Scola B.

Culture of SARS-CoV-2 in a panel of laboratory cell lines, permissivity, and differences in growth profile.

Eur. J. Clin. Microbiol. Infect. Dis. 40:477-484(2021)"